Key facts
- Revisto’s last known valuation is $15.5M.
- It has raised $6.0M; the latest was Seed Round ($4.0M) in Nov 2024.
- Notable investors include Tau Ventures, Arkin Capital, LiveOak Ventures, Eli Lilly.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Revisto
- ·The full record, as it builds
Funding rounds
No funding rounds for Revisto are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Revisto
Operator of an AI-driven review platform intended for streamlining the medical, legal, and regulatory (MLR) review process of marketing materials. The company's platform automates content evaluation for quality, compliance, and accuracy, provides actionable recommendations based on unique organizational data, supports efficient collaboration, and integrates with existing workflows, enabling pharmaceutical, medtech, and digital agency markets to accelerate time-to-market, reduce manual work, and minimize compliance risks while maintaining high standards.
- Sector
- Information Technology
- HQ
- San Antonio, TX, United States
- Founded
- 2023
- Employees
- 17
- Website
- revisto.com/
- Ownership
- Privately Held (backing)
Revisto doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Revisto shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Revisto in its N-PORT filings yet. We sweep new filings monthly.